Year

Category

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

July 09, 2020

MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga,… Read More

Tris Pharma Launches New Corporate Website

June 25, 2020

MONMOUTH JUNCTION, NJ, June 25, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced the launch of a new… Read More

Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic

March 17, 2020

MONMOUTH JUNCTION, NJ, March 17, 2020 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved... Read More

APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD

January 17, 2020

MONMOUTH JUNCTION, NJ, January 17, 2020 / PRNewswire/ - The American Professional Society of ADHD and Related Disorders (APSARD) is a U.S.-based international... Read More

Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019

November 07, 2019

MONMOUTH JUNCTION, NJ, November 7, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved... Read More

Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team

October 30, 2019

FOR IMMEDIATE RELEASE - MONMOUTH JUNCTION, NJ, October 30, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust... Read More

Tris Pharma Strengthens Its Branded Commercial Leadership Team

September 04, 2019

Todd Killian to lead Market Access and Trade Relations Scott Brunetto to lead Commercial Operations and Analytics MONMOUTH JUNCTION, NJ,... Read More

Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee

August 14, 2019

FOR INFORMATION Cheryl Patnick (732) 823-4940 cpatnick@trispharma.com MONMOUTH JUNCTION, NJ, August 14, 2019 / PRNewswire/ - Tris Pharma,... Read More

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

January 29, 2019

FOR IMMEDIATE RELEASE – January 29, 2019 – Monmouth Junction, NJ, Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3)... Read More

Information Related to the Voluntary Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL

January 28, 2019

Tris Pharma recently issued an expansion of the voluntary recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL and an... Read More

Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris’ LiquiXR® Technology at the 2019 APSARD Annual Meeting

January 17, 2019

MONMOUTH JUNCTION, NJ, January 17, 2019 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that... Read More

Information Related to the Voluntary Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL

December 06, 2018

Tris Pharma recently issued a voluntary recall and an associated press release regarding 3 batches (00717009A, 00717015A, 00717024A) of Infant’s Ibuprofen... Read More

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

December 05, 2018

MONMOUTH JUNCTION, NJ, December 05, 2018 / PRNewswire/ -– Monmouth Junction, NJ, Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’... Read More

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

November 12, 2018

The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1... Read More

Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra® XR

November 05, 2018

ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization... Read More

Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists

October 25, 2018

MONMOUTH JUNCTION, NJ, October 24, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that... Read More

Tris Pharma Announces Hiring of Chief Commercial Officer

October 10, 2018

MONMOUTH JUNCTION, NJ, October 10, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative... Read More

Deerfield Provides $125 million Debt Financing to Tris Pharma

October 04, 2018

Deerfield provides growth capital financing to Tris Pharma New York, New York – October 4, 2018 – Deerfield announced today it provided $125 million to... Read More

Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

September 25, 2018

MONMOUTH JUNCTION, NJ, September 25, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative... Read More

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

August 27, 2018

MONMOUTH JUNCTION, NJ, August 27, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based... Read More

Tris Pharma’s Results from a Laboratory Classroom Study of DYANAVEL® XR in Children with ADHD Featured at APSARD

February 09, 2017

MONMOUTH JUNCTION, N.J., February 9, 2017 - Tris Pharma, Inc. (“Tris”) announced that results from a laboratory classroom study of DYANAVEL XR... Read More

FDA accepts CCP-08 NDA for full review

December 20, 2016

Vernalis plc and Tris Pharma, Inc. (“Tris”) are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has accepted the CCP-08 New... Read More

FDA Accepts CCP-07 NDA for Full Review

September 05, 2016

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-07 New Drug... Read More

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD

April 19, 2016

MONMOUTH JUNCTION, N.J., April 19, 2016 - Tris Pharma, Inc. ("Tris") announces today the launch of DYANAVEL™ XR (amphetamine), CII, the... Read More

Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet

December 16, 2015

MONMOUTH JUNCTION, NJ, December 16, 2015 / PRNewswire/ - Tris Pharma, Inc. ("Tris") is pleased to announce that the U.S. Food and Drug Administration ("FDA")... Read More

Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII

December 07, 2015

NEW YORK, N.Y., December 7 -- Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer... Read More

Tris Pharma Receives FDA Approval of Dyanavel™ XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children

October 20, 2015

MONMOUTH JUNCTION, N.J., October 20, 2015 -- Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved... Read More

Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire

October 01, 2015

Monmouth Junction, N.J., Oct. 1, 2015 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery... Read More

Vernalis PLC launches Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing

September 07, 2015

Vernalis plc (LSE: VER) and Tris Pharma today announce that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral... Read More

FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children

August 13, 2015

CHARLOTTE, N.C., August 13, 2015; - FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral... Read More

Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand

June 29, 2015

MONMOUTH JUNCTION, N.J., June 29, 2015; - Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement... Read More

Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel™ XR

May 21, 2015

MONMOUTH JUNCTION, N.J., May 21, 2015; - Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Administration ("FDA") has accepted for review its... Read More

Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR

May 01, 2015

MONMOUTH JUNCTION, N.J., May 1, 2015; - Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the... Read More

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

September 15, 2014

MONMOUTH JUNCTION, N.J., September 15, 2014; - Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug... Read More

Tris Pharma Receives NJBIA Award for Excellence

August 27, 2014

MONMOUTH JUNCTION, N.J., August 27, 2014; - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,... Read More

Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept

July 22, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their... Read More

Submission of Tuzistra™ XR (CCP-01) NDA to FDA

June 30, 2014

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug... Read More

Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept

April 01, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-07, the second programme to achieve this milestone in... Read More

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01

February 01, 2014

Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study... Read More

Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension

September 04, 2013

MONMOUTH JUNCTION, N.J. & CHARLOTTE, N.C., September 4, 2013 -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive... Read More

Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution

July 10, 2013

MONMOUTH JUNCTION, N.J., July 10, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today... Read More

Tris Pharma Hires President for Generic Pharmaceuticals Business

June 20, 2013

MONMOUTH JUNCTION, N.J., June 20, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today... Read More

Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey

May 02, 2013

MONMOUTH JUNCTION, N.J., May 2, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today... Read More

FDA Approves Tris Pharma’s New Drug Application for KarbinalTM ER (carbinoxamine maleate) Extended-release Oral Suspension

April 03, 2013

MONMOUTH JUNCTION, N.J., April 3, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today... Read More

First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris

March 11, 2013

MONMOUTH JUNCTION, N.J., March 11, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,... Read More

Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States

January 14, 2013

NEW YORK, N.Y., January 14 - Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral... Read More

Pfizer To Acquire NextWave Pharmaceuticals, Inc.

October 22, 2012

NEW YORK--(BUSINESS WIRE[1])--Pfizer Inc [2]. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals [3], a privately held, specialty... Read More

Perrigo and Tris Pharma launch store brand version of Delsym®

August 27, 2012

ALLEGAN, Mich. and MONMOUTH JUNCTION, NJ – August 27, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial... Read More

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals

July 11, 2012

MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug... Read More

Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension

May 31, 2012

MONMOUTH JUNCTION, N.J., May 31; /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company announced today that the US Food and Drug... Read More

Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension

May 30, 2012

ALLEGAN, Mich. – May 30, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval... Read More

Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market

February 06, 2012

Vernalis plc (Vernalis), a UK development stage pharmaceutical company listed on the London Stock Exchange (LSE:VER) and Tris Pharma Inc (Tris) a privately... Read More

Tris Pharma Announces US Patent Grant Covering Platform Technology

January 06, 2012

MONMOUTH JUNCTION, N.J., January 6; /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced the US grant of its core technology... Read More

Contact us

Interested in learning more about our products, pipeline, and partnerships?